HR+/HER2- Metastatic Breast Cancer Progression Improved With Sac-TMTByAndrea Eleazar, MHSOctober 19th 2025
Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast CancerByChris RyanOctober 19th 2025
Similar Incidence of Second Primary Tumors After Libtayo or Placebo for CSCCByJax DiEugenioOctober 18th 2025
Enhertu Reduces Risk of Invasive Disease or Death in HER2+ Breast CancerByAshling WahnerOctober 18th 2025